文献速递神经MR

在2021年WHO更新版基础上加入影像组学可改善已知EGFR扩增和TERT启动子突变状态的IDH野生型组织学低级别胶质瘤的预后预测

Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
PubMed 文献 · Eur Radiol · 2022-06-28

研究纳入61例IDH野生型组织学低级别胶质瘤患者作为机构训练集,32例来自癌症基因组图谱作为测试集,提取186个常规MRI影像组学特征并构建影像组学风险评分。加入影像组学风险评分后,总生存预测的iAUC在训练集从0.775升至0.910,内部验证从0.726升至0.884,外部验证从0.683升至0.705,外部验证集证实其预后意义(p=0.001)。

要点

  • 影像组学风险评分可独立预测总生存(HR=48.08,p=0.001)。
  • 加入影像组学风险评分后,训练集iAUC从0.775升至0.910。
  • 外部验证集证实影像组学风险评分的预后意义(p=0.001)。

核心结论

  • 将影像组学与临床病理特征(包括EGFR扩增和TERT启动子突变状态)整合,可改善IDH野生型组织学低级别胶质瘤患者的总生存预测。

研究设计与样本

  • 回顾性纳入61例IDH野生型组织学低级别胶质瘤患者的术前MRI作为机构训练集,测试集为来自癌症基因组图谱的32例患者,提取186个常规MRI影像组学特征,采用弹性网络构建总生存的影像组学风险评分,并行多变量Cox回归分析。

诊断标准与关键数值

  • 影像组学风险评分独立预测总生存(HR=48.08,p=0.001);加入影像组学风险评分后,训练集iAUC从0.775升至0.910,内部验证集从0.726升至0.884,外部验证集从0.683升至0.705;1年总生存NRI内部验证为0.497、外部验证为0.733。

临床应用与阅片要点

  • 作者认为,将影像组学与临床病理特征(包括EGFR扩增和TERT启动子突变状态)整合可改善IDH野生型组织学低级别胶质瘤患者的总生存预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess whether radiomic features could improve the accuracy of survival predictions of IDH-wildtype (IDHwt) histological lower-grade gliomas (LGGs) over clinicopathological features.

METHODS: Preoperative MRI data of 61 patients with IDHwt histological LGGs were included as the institutional training set. The test set consisted of 32 patients from The Cancer Genome Atlas. Radiomic features (n = 186) were extracted using conventional MRIs. The radiomics risk score (RRS) for overall survival (OS) was derived from the elastic net. Multivariable Cox regression analyses with clinicopathological features (including epidermal growth factor receptor [EGFR] amplification and telomerase reverse transcriptase promoter [TERTp] mutation status) and the RRS were performed. The integrated area under the receiver operating curves (iAUCs) from the models with and without the RRS were compared. The net reclassification index (NRI) for 1-year OS was also calculated. The prognostic value of the RRS was evaluated using the external validation set.

RESULTS: The RRS independently predicted OS (hazard ratio = 48.08; p = 0.001). Compared with the clinicopathological model alone, adding the RRS had a better OS prediction performance (iAUCs 0.775 vs. 0.910), which was internally validated (iAUCs 0.726 vs. 0.884, 1-year OS NRI = 0.497), and a similar trend was found on external validation (iAUCs 0.683 vs. 0.705, 1-year OS NRI = 0.733). The prognostic significance of the RRS was confirmed in the external validation set (p = 0.001).

CONCLUSIONS: Integrating radiomics with clinicopathological features (including EGFR amplification and TERTp mutation status) can improve survival prediction in patients with IDHwt LGGs.

KEY POINTS: • Radiomics risk score has the potential to improve survival prediction when added to clinicopathological features (iAUCs increased from 0.775 to 0.910). • NRIs for 1-year OS showed that the radiomics risk score had incremental value over the clinicopathological model. • The prognostic significance of the radiomics risk score was confirmed in the external validation set (p = 0.001).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Park, Kim, Park, et al. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. Eur Radiol. 2022. PMID: 35763095. doi:10.1007/s00330-022-08941-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。